Cell line · CVCL_1352
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Alcohol exposure promotes cell communication network 1 cleavage in esophageal adenocarcinoma cells exclusively. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Noncanonical RNA-Binding Function of NQO1 Drives Angiogenesis in Esophageal Squamous Cell Carcinoma via Extracellular Vesicle-Mediated AGRN Transfer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PDIA6 promotes the cell proliferation of ESCC by enhancing the disulfide bond formation in TRAF4. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrative bioinformatics and experiments identify RIBC2 as a key regulator in the esophageal cancer. | PLoS One | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotype-to-Phenotype Mapping of Somatic Clonal Mosaicism via Single-Cell Co-Capture of DNA Mutations and mRNA Transcripts. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Modification-specific Proteomic Analysis Reveals Cysteine S-Palmitoylation Involved in Esophageal Cancer Cell Radiation. | ACS Omega | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma. | Technol Cancer Res Treat | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | Mol Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Androgen Receptor/AP-1 Activates UGT2B15 Transcription to Promote Esophageal Squamous Cell Carcinoma Invasion. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Fibroblasts in metastatic lymph nodes confer cisplatin resistance to ESCC tumor cells via PI16. | Oncogenesis | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer. | Mol Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis. | EBioMedicine | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1352/papers